Armistice Capital LLC Has $9.32 Million Stock Holdings in McKesson Corporation $MCK

Armistice Capital LLC boosted its stake in shares of McKesson Corporation (NYSE:MCK) by 94.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,363 shares of the company’s stock after purchasing an additional 5,510 shares during the period. Armistice Capital LLC’s holdings in McKesson were worth $9,321,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of MCK. Norges Bank acquired a new position in McKesson during the fourth quarter valued at approximately $1,651,137,000. Swedbank AB boosted its position in McKesson by 42.2% during the fourth quarter. Swedbank AB now owns 886,283 shares of the company’s stock valued at $727,009,000 after purchasing an additional 263,189 shares during the last quarter. SurgoCap Partners LP boosted its position in McKesson by 68.7% during the third quarter. SurgoCap Partners LP now owns 452,261 shares of the company’s stock valued at $349,390,000 after purchasing an additional 184,106 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its position in McKesson by 73.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 432,578 shares of the company’s stock valued at $354,839,000 after purchasing an additional 183,590 shares during the last quarter. Finally, Danica Pension Livsforsikringsaktieselskab acquired a new position in McKesson during the third quarter valued at approximately $135,352,000. 85.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at McKesson

In related news, CEO Brian S. Tyler sold 4,929 shares of the business’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $763.00, for a total value of $3,760,827.00. Following the completion of the sale, the chief executive officer directly owned 22,845 shares in the company, valued at approximately $17,430,735. The trade was a 17.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michele Lau sold 3,550 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total value of $2,701,869.50. Following the completion of the sale, the executive vice president owned 3,247 shares of the company’s stock, valued at approximately $2,471,259.23. This trade represents a 52.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 11,822 shares of company stock worth $8,986,212 in the last ninety days. 0.08% of the stock is currently owned by company insiders.

McKesson Trading Down 0.8%

Shares of NYSE MCK opened at $779.00 on Thursday. The firm has a market cap of $91.21 billion, a P/E ratio of 20.25, a price-to-earnings-growth ratio of 1.29 and a beta of 0.31. McKesson Corporation has a 1-year low of $637.00 and a 1-year high of $999.00. The business’s 50 day moving average is $792.46 and its 200-day moving average is $843.97.

McKesson (NYSE:MCK) last announced its earnings results on Thursday, May 7th. The company reported $11.69 earnings per share for the quarter, topping analysts’ consensus estimates of $11.56 by $0.13. The company had revenue of $96.30 billion for the quarter, compared to analyst estimates of $101.35 billion. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The firm’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter last year, the company earned $10.12 earnings per share. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Analysts forecast that McKesson Corporation will post 44.28 EPS for the current year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be paid a dividend of $0.82 per share. The ex-dividend date is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio (DPR) is 8.53%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on MCK. Citigroup dropped their price objective on McKesson from $975.00 to $945.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. William Blair began coverage on McKesson in a research note on Tuesday, April 28th. They issued an “outperform” rating on the stock. Raymond James Financial set a $970.00 price objective on McKesson in a research note on Thursday, March 5th. Bank of America dropped their price objective on McKesson from $1,040.00 to $1,000.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Finally, Wall Street Zen upgraded McKesson from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $960.53.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.